Where To Withdraw Money From Bluebird

Why Bluebird Bio Stock Plunged Today

Two analysts downgraded the biotech stock.

Key Points

Goldman Sachs downgraded Bluebird from neutral to sell.
Morgan Stanley downgraded the stock from equal weight to underweight.
Concerns about Bluebird include its near-term commercialization challenges and recent spin-off.

What happened

Shares of Bluebird Bio (NASDAQ:BLUE) were plunging 19.3% lower as of 3:42 p.m. EST on Monday. The sharp decline came after two analysts downgraded Bluebird.

Goldman Sachs (NYSE:GS) analyst Salveen Richter downgraded the biotech stock from neutral to sell. Richter set a price target of $10, nearly 24% below Bluebird's closing price on Friday.

Morgan Stanley (NYSE:MS) analyst Matthew Harrison also downgraded the stock from equal weight to underweight (the equivalent of a sell recommendation). Harrison established a price target of $11, roughly 16% lower than Bluebird's closing price on Friday.

A person giving a thumbs down sign.

Image source: Getty Images.

So what

Morgan Stanley's Harrison thinks that "commercialization will remain challenging" for Bluebird. That seems to be a fair assessment.

Bluebird announced in August that it planned to exit the European market for its gene therapies. In October, the company said that it would withdraw its regulatory applications for Skysona with the European Union and the U.K.

There's also some uncertainty about Bluebird's spin-off of its oncology business. The oncology unit is now a separate entity, 2seventy Bio (NASDAQ:TSVT). Bluebird will continue to focus on genetic diseases.

However, Wall Street analysts tend to focus more heavily on the near-term prospects for a stock than they do the long-term prospects. It's possible that Bluebird's spin-off strategy could pay off for investors over the long run.

Now what

Bluebird hopes to receive acceptance of its biologics license application (BLA) for beti-cel in treating beta-thalassemia this month. The company is talking with the U.S. Food and Drug Administration (FDA) about lifting the clinical hold on eli-cel (Lenti-D). It plans to submit a BLA for the therapy in treating cerebral adrenoleukodystrophy (CALD), a rare genetic disease, by year's end.

This article represents the opinion of the writer, who may disagree with the "official" recommendation position of a Motley Fool premium advisory service. We're motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Motley Fool Returns

Stock Advisor S&P 500

669% 145%

Join Stock Advisor

Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.

Stock Advisor launched in February of 2002. Returns as of 11/24/2021.

Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return Chart Showing the Cumulative Growth of a $10,000 Investment in Stock Advisor